Symphony IL-6 Study in Patients at Risk of Severe Sepsis

Status Recruiting

Clinical Trial Summary

Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing. Symphony IL-6 comprises two components, the Symphony Fluorescence Immunoanalyzer and the Symphony IL-6 Cartridge. Whole blood is added to the cartridge and then up to six cartridges can be inserted into the immunoanalyzer. After 20 minutes a readout and printout are given with a quantitative IL-6 concentration. The used cartridges are fully enclosed and can be easily disposed of in general hospital bio-waste. Given the nature of this device and its portability, there is potential for future deployment in a near patient setting. This study is to establish an interleukin-6 (IL-6) cutoff value using the Symphony IL-6 test for patients at high risk of severe sepsis caused by a COVID-19 and/or influenza infection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05665153
Study type	Observational
Source	Bluejay Diagnostics, Inc.
Contact	Jason Cook, Ph.D.
Phone	9787935876
Email	clinical@bluejaydx.com
Status	Recruiting
Phase
Start date	November 22, 2022
Completion date	November 21, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04804306` - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed	`NCT04227652` - Control of Fever in Septic Patients	N/A
Recruiting	`NCT04005001` - Machine Learning Sepsis Alert Notification Using Clinical Data	Phase 2
Recruiting	`NCT02899143` - Short-course Antimicrobial Therapy in Sepsis	Phase 2
Completed	`NCT02539147` - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis	N/A
Completed	`NCT01932814` - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?	N/A
Completed	`NCT01929772` - German Lactat Clearance in Severe Sepsis	N/A
Completed	`NCT01449721` - Preemptive Resuscitation for Eradication of Septic Shock	N/A
Active, not recruiting	`NCT01162109` - Zinc Therapy in Critical Illness	Phase 1
Not yet recruiting	`NCT01211899` - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock	N/A
Completed	`NCT00934011` - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections	N/A
Recruiting	`NCT00335907` - Protocol-driven Hemodynamic Support for Patients With Septic Shock	N/A
Completed	`NCT00463645` - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients	N/A
Completed	`NCT02361528` - GM-CSF to Decrease ICU Acquired Infections	Phase 3
Completed	`NCT02734550` - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis	N/A
Completed	`NCT02973243` - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III	N/A
Terminated	`NCT03895853` - Early Metabolic Resuscitation for Septic Shock	Phase 2
Completed	`NCT01945983` - Early Use of Norepinephrine in Septic Shock Resuscitation	N/A
Completed	`NCT01598831` - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy	Phase 3
Enrolling by invitation	`NCT02258984` - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial	N/A